Roche to buy 89bio in deal worth up to $3.5B, picking up MASH drug

Roche announced the acquisition of 89bio for up to $3.5 billion, paying $14.50 per share in cash—a nearly 80% premium over 89bio’s closing price—plus a contingent value right up to $6 per share. This strategic move secures 89bio's experimental MASH drug, pegozafermin, signaling Roche's entry into the increasingly attractive market for non-alcoholic steatohepatitis treatments and reflecting the high value placed on innovative therapies for this liver disease.

Analysis

Roche has announced a definitive agreement to acquire 89bio in a deal with a potential value of up to $3.5 billion, marking a significant strategic entry into the high-interest MASH therapeutic area. The transaction structure includes a cash payment of $14.50 per share for 89bio (ETNB), representing a substantial premium of nearly 80% over its last closing price and an equity value of $2.4 billion. The inclusion of a contingent value right (CVR) worth up to an additional $6 per share suggests the ultimate valuation is tied to future developmental or regulatory milestones for 89bio's lead asset, pegozafermin. This experimental drug for MASH, a liver disease linked to obesity, is the centerpiece of the acquisition, highlighting the premium large pharmaceutical companies are willing to pay for promising, de-risked assets in competitive and large-market indications. The deal underscores a broader M&A trend in the biotech sector where established players are utilizing acquisitions to bolster their pipelines.

Key Decisions for Investors

• Shareholders of 89bio (ETNB) should consider the near-certainty of the $14.50 cash offer against the speculative value of the $6 contingent value right when deciding whether to hold through the acquisition or liquidate their positions.
• Investors should view this deal as a strong validation of the MASH therapeutic space and may consider increasing exposure to other clinical-stage biotechs with promising MASH drug candidates, as they could be future M&A targets.
• For investors in Roche, this bolt-on acquisition signals a proactive strategy to expand its pipeline into new growth areas but is unlikely to materially impact near-term financials given Roche's significant scale.